||Jeffrey R. Curtis, MD, MS, MPH
Professor of Medicine
Willaim J. Koopman Endowed Professor in Rheumatology and Immunology
Director, UAB Arthritis Clinical Intervention Program (ACIP)
Co-Director, UAB Center for Education and Research on Therapeutics (CERTs)
Co-Director, UAB PharmacoEpidEmiology and phaRmcoeconomics (PEER) Unit
University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology
Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). He is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, which has a major emphasis on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Additionally, as the Director of the UAB Arthritis Clinical Intervention Program, he leads the clinical trials unit for the rheumatology division at UAB, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. He has been awarded the William J. Koopman Endowed Professorship in Rheumatology and Immunology.
Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. His subsequent work in Clinical Informatics was done at Stanford University. He is board-certified in rheumatology.
The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis?s research interests. He served on the Core Expert Panel for the ACR?s 2008 and 2012 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA and is part of the forthcoming 2015 ACR Recommendations. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network focused on RA, psoriasis, and PsA.
Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR's task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He also served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.
Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), and the American Society of Bone and Mineral Research (ASBMR). He has authored more than 200 peer-reviewed articles and book chapters. He is on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R).